维罗纳制药2024财年实现净利润-1.73亿美元,同比减少216.97%

市场透视
07 Mar

3月7日,维罗纳制药(VRNA.US)公布财报,公告显示公司2024财年净利润为-1.73亿美元,同比减少216.97%;其中营业收入为42.30百万美元,每股基本收益为-2.13美元。从资产负债表来看,维罗纳制药(VRNA.US)总负债2.70亿美元,其中短期债务1.12百万美元,资产负债比为1.76,流动比率为0.11。机构评级:截至2025年3月7日,当前有9家机构对维罗纳制药目标价做出预测...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10